Fatigue Syndrome, Chronic
A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 3 trials (15)
Phase 2 trials (20)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (18)
- Jazz Pharmaceuticals
- Shire
- Pfizer
- Laboratorios Viñas, S.A.
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- University of London
- University of Washington
- Hoosier Cancer Research Network
- Radboud University
- Rochester Center for Behavioral Medicine
- Rutgers University
- University of Medicine and Dentistry of New Jersey
- Universidad Autonoma de Barcelona
- Charles Drew University
- Department of Veteran Affairs
- Laboratorio Echevarne
- Ghent University
Organization Involved with Phase 3 Indications (21)
- Symyoo
- Green Cross Corporation
- Hemispherx Biopharma
- Eli Lilly
- Ajou University
- Harvard University
- Norwegian University of Science and Technology
- Osaka University
- University Hospital of North Norway
- University of Bergen
- Chonbuk National University
- Kangbuk Samsung Hospital
- University of Cincinnati
- Hunter-Hopkins Center, P.A.
- Telemark Hospital Trust
- Bateman Horne Center
- The Kavli Foundation
- MEandYou Foundation
- The Norwegian ME association
- VITAE NATURAL NUTRITION, S.L.
- Government of Norway
Organization Involved with Phase 2 Indications (12)
- Chelsea Therapeutics
- PharmaLundensis AB
- National Institutes of Health (NIH)
- Center for Health, Exercise and Sport Sciences, Serbia
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cornell University
- Duke University
- Stanford University
- University of Oslo
- Quadram Institute
- Umea University
- Probare i Lund AB
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (9)